UAE Cancer Immunotherapy Market Report 2022 to 2030

UAE Cancer Immunotherapy Market Analysis

$ 3999

UAE's cancer immunotherapy market is expected to witness growth from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-30. The increasing incidence of cancer in the UAE along with favorable government initiatives to promote the use of immunotherapy treatment in the UAE are responsible for the growth of the market. The UAE cancer immunotherapy market is segmented by type, application, and end user. Lamba, Neopharma, and Bayer are the major players in the UAE cancer immunotherapy market.

ID: IN10AEPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Parul Choudhary

Buy Now

UAE Cancer Immunotherapy Market Executive Analysis

UAE's cancer immunotherapy market is expected to witness growth from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-30. The future holds growth for Dubai's healthcare industry. According to the Dubai Chamber of Commerce and Industry, revenue generated within the whole UAE healthcare sector is anticipated to increase by 7.5% annually to reach $10.7 Bn by 2025. Meanwhile, it is anticipated that healthcare spending will increase to 4.6% of GDP by 2026 and 5.1% of GDP by 2029. With increased government initiatives, the UAE healthcare business is expanding at an astounding rate. Additionally, the UAE government is significantly enhancing and extending its healthcare system in order to create a powerful, top-notch healthcare infrastructure. To improve the current infrastructure and match the caliber of services provided in other nations, the government is also promoting private sector participation.

WHO estimates that by 2030, there may be up to 961,098 more cancer cases than there were in 2012 (555,318). The high incidence of breast, lung, thyroid, cervical, and colorectal cancer in the UAE is a result of an unhealthy lifestyle and insufficient medical care.

Cancer immunotherapy is a new subject in the UAE that is attracting more and more interest from patients and medical professionals. Utilizing the body's natural immune system to combat cancer cells is how immunotherapy treatment functions. Immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines are just a few of the cancer immunotherapy therapies offered in the UAE. To provide patients with the best results, these treatments are frequently applied in conjunction with conventional cancer therapies like chemotherapy or radiation therapy. The Abu Dhabi Stem Cell Center and the Dubai Biotechnology and Research Park are two examples of the UAE government's investments in cancer research and treatment. These programs give patients access to the most recent therapies and technologies while also advancing the field of cancer immunotherapy in the UAE.

UAE Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

Incidences of cancer have been rising in the UAE in recent years, and lifestyle choices including smoking, eating poorly, and not exercising have all contributed to the rise. The market for cancer immunotherapy treatments is significantly expanded as a result of the rising incidence of cancer. The government of the UAE has made significant investments in the growth of its healthcare infrastructure and services, contributing to the country's high level of healthcare spending. This investment is anticipated to aid in the UAE cancer immunotherapy market expansion. Through programs like the Dubai Future Accelerators program, which seeks to unite established and startup healthcare businesses to create fresh healthcare solutions, the UAE government has been promoting healthcare innovation. The development of novel cancer immunotherapy therapies is anticipated to be accelerated by this financing.

Market Restraints

Cancer immunotherapy medications are expensive, and some patients do not have insurance coverage. There is a shortage of qualified medical personnel who can provide immunotherapy. delays in the approval of drugs due to regulatory issues. Limited knowledge of the possible adverse effects and mechanisms of action of immunotherapeutic medicines. These factors limit the expansion of the UAE cancer immunotherapy market.

Competitive Landscape

Key Players

NewBridge Pharmaceuticals (ARE)
Pharmax (ARE)
Shalina Healthcare (ARE)
Lamba (ARE)
Neopharma (ARE)
Bayer
Bristol-Myers Squibb
Eli Lily
F. Hoffmann-La Roche
Pfizer
Johnson & Johnson
Merck

Notable Deals

April 2023- The Ministry of Health and Prevention in the UAE has approved the use of Merck Sharp and Dohme's (MSD) immunotherapy for a novel indication that will provide patients with triple-negative breast cancer (TNBC) hope. The introduction of this new medication will give patients with TNBC newfound optimism. Now, they can have this immunotherapy from both public and private facilities. In addition, he confirmed that when using the medicine instead of simply chemotherapy, the reoccurrence rate of TNBC was lower.

Healthcare Policies and Regulatory Landscape

The "Thiqa" program, which is the country's national health insurance policy, covers cancer treatment in the UAE. All UAE citizens and foreign immigrants are given basic health insurance coverage through this scheme. Chemotherapy, radiation therapy, and surgery are all covered under the Thiqa program for cancer treatment. The type of cancer and the stage of the disease, however, can affect the scope of coverage. Patients may need to pay out-of-pocket for some treatments, like immunotherapy and targeted medicines, or look for coverage through private health insurance policies since some treatments might not be covered by the Thiqa program. The UAE government has put in place a fee-for-service reimbursement approach for healthcare providers. This implies that, as opposed to a capitation model that pays a fixed sum per patient, healthcare providers are paid according to the services they render. This paradigm may encourage healthcare providers to offer additional services, such as cancer treatments, but it may also increase patient healthcare expenses.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
PD-1/PD-L1
CTLA-4

By Application (Revenue, USD Billion):

Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)
Cancer Research Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Lamba, Neopharma, and Bayer are the major players in the UAE cancer immunotherapy market.

The UAE cancer immunotherapy market is expected to grow from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-2030.

The UAE cancer immunotherapy market is segmented by type, application, and end user.